MAGEA3 and lung cancer: As MAGE-3, NY-SAR-35, NY-ESO-1 and MAGE-1 were expressed with a high percentage and specificity in lung cancer tissues, their products might be ideal for antigen targets for lung cancer immunotherapy (Fig. 2).